Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.35 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.33 |
| ▸ | GCG | P01275 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | F9 | P00740 | 1/20 | 0.33 |
| ▸ | VEGFA | P15692 | 1/20 | 0.33 |
| ▸ | FLT1 | P17948 | 1/20 | 0.33 |
| ▸ | TYMS | P04818 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1390250 | 1.00 | GPBAR1 (0.41) | GPBAR1KMT2ASLC6A9EGLN1BRD4 | |
| SCHEMBL1390044 | 0.93 | GPBAR1 (0.39) | GPBAR1KMT2ASLC6A9BRD4SLC6A5 | |
| SCHEMBL1390040 | 0.93 | GPBAR1 (0.39) | GPBAR1KMT2ASLC6A9BRD4SLC6A5 | |
| SCHEMBL1389596 | 0.90 | GPBAR1 (0.41) | GPBAR1KMT2ASLC6A9EGLN1SLC6A5 | |
| SCHEMBL1389730 | 0.90 | GPBAR1 (0.41) | GPBAR1KMT2ASLC6A9EGLN1SLC6A5 | |
| SCHEMBL1389593 | 0.90 | GPBAR1 (0.41) | GPBAR1KMT2ASLC6A9EGLN1SLC6A5 | |
| SCHEMBL1389743 | 0.89 | GPBAR1 (0.51) | GPBAR1BRD4F9 | |
| SCHEMBL1389744 | 0.89 | GPBAR1 (0.51) | GPBAR1BRD4F9 | |
| SCHEMBL1389738 | 0.89 | GPBAR1 (0.51) | GPBAR1BRD4F9 | |
| SCHEMBL368294 | 0.86 | GPBAR1 (0.42) | GPBAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | claimed |
| EP-2593426-B1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | HOFFMANN LA ROCHE (CH) | 2014-08-20 | — | — | EP | disclosed |
| US-8765730-B2 | 1-hydroxyimino-3-phenyl-propanes | Hoffmann-La Roche Inc (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010190-A1 | 1-HYDROXYIMINO-3-PHENYL-PROPANES | GPBAR1, GPR119, ADRB1 | GPBAR1 1/4885KMT2A 3981/4885SLC6A9 1778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.